Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6403114 | ALKERMES | Preparation of biodegradable, biocompatible microparticles containing a biologically active agent |
May, 2017
(6 years ago) | |
US5916598 | ALKERMES | Preparation of biodegradable, biocompatible microparticles containing a biologically active agent |
May, 2017
(6 years ago) | |
US5792477 | ALKERMES | Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent |
May, 2017
(6 years ago) | |
US6194006 | ALKERMES | Preparation of microparticles having a selected release profile |
Dec, 2018
(5 years ago) | |
US6379703 | ALKERMES | Preparation of microparticles having a selected release profile |
Dec, 2018
(5 years ago) | |
US6596316 | ALKERMES | Preparation of microparticles having a selected release profile |
Dec, 2018
(5 years ago) | |
US6395304 | ALKERMES | Apparatus and method for preparing microparticles |
Nov, 2019
(4 years ago) | |
US6495166 | ALKERMES | Apparatus and method for preparing microparticles using in-line solvent extraction |
Nov, 2019
(4 years ago) | |
US6939033 | ALKERMES | Method and apparatus for preparing microparticles using in-line solvent extraction |
Nov, 2019
(4 years ago) | |
US6537586 | ALKERMES | Apparatus and method for preparing microparticles |
Nov, 2019
(4 years ago) | |
US6713090 | ALKERMES | Apparatus and method for preparing microparticles |
Nov, 2019
(4 years ago) | |
US6331317 | ALKERMES | Apparatus and method for preparing microparticles |
Nov, 2019
(4 years ago) | |
US6264987 | ALKERMES | Method for preparing microparticles having a selected polymer molecular weight |
May, 2020
(3 years ago) | |
US6379704 | ALKERMES | Method for preparing microparticles having a selected polymer molecular weight |
May, 2020
(3 years ago) | |
US6534092 | ALKERMES | Method for preparing microparticles having a selected polymer molecular weight |
May, 2020
(3 years ago) | |
US6667061 | ALKERMES | Preparation of injectable suspensions having improved injectability |
May, 2020
(3 years ago) | |
US7799345 | ALKERMES | Preparation of injectable suspensions having improved injectability |
May, 2020
(3 years ago) | |
US6495164 | ALKERMES | Preparation of injectable suspensions having improved injectability |
May, 2020
(3 years ago) | |
US7919499 | ALKERMES | Naltrexone long acting formulations and methods of use |
Oct, 2029
(5 years from now) |
Vivitrol is owned by Alkermes.
Vivitrol contains Naltrexone.
Vivitrol has a total of 19 drug patents out of which 18 drug patents have expired.
Expired drug patents of Vivitrol are:
Vivitrol was authorised for market use on 13 April, 2006.
Vivitrol is available in for suspension, extended release;intramuscular dosage forms.
Vivitrol can be used as treatment of alcohol dependence.
The generics of Vivitrol are possible to be released after 15 October, 2029.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication(I-631) | Oct 12, 2013 |
Drugs and Companies using NALTREXONE ingredient
Market Authorisation Date: 13 April, 2006
Treatment: Treatment of alcohol dependence
Dosage: FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR